

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**GUIDANCE EXECUTIVE (GE)**

**Consideration of consultation responses on review proposal**

**Review of TA191; Capecitabine for the treatment of advanced gastric cancer**

This guidance was issued July 2010 with a review date of May 2013.

**Background**

At the GE meeting of 16 April 2013 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

<b>Proposal put to consultees:</b>	TA191 should be transferred to the 'static guidance list'.
<b>Rationale for selecting this proposal</b>	There is no new evidence to suggest that the recommendations of TA191 should change nor any ongoing trials of capecitabine that might be expected lead to a change in the recommendations. There has been no relevant change to the price of capecitabine. It anticipated that generic formulations will be available in the near future.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

<b>Recommendation post consultation:</b>	TA191 will be transferred to the 'static guidance list'.
--	--

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Roche Products	Agree	We support the approach NICE is undertaking to move this guidance to the static list. We have no additional evidence to add at this time.	Comment noted.
Royal College of Nursing	No comment	Feedback received from nurses working in this area of health suggest that there are no comments to submit on behalf of the Royal College of Nursing to inform on the review proposal of the above technology.	No action.
Medicines and Healthcare Products Regulatory Agency	No comment	We have no comments for this appraisal.	No action.

**No response received from:**

<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Abbott Gmbh &amp; Co. (capecitabine)</li> <li>• Accord Healthcare (capecitabine)</li> <li>• Actavis UK (capecitabine)</li> <li>• AstraZeneca (capecitabine)</li> <li>• Krka (capecitabine)</li> <li>• Teva UK (capecitabine)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Cancer52</li> <li>• Cancer Black Care</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> </ul>
--	---

- Cancer Equality
- Equalities National Council
- GIST support UK
- Helen Rollason Heal Cancer Charity
- Independent Age
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- National Council for Palliative Care
- Oesophageal Patients Association
- Rarer Cancers Foundation
- Sarcoma UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder
- Tenovus

#### Professional groups

- Association of Cancer Physicians
- British Association for Services to the Elderly
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Society of Gastroenterology
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Pathologists

- NHS Confederation
- Public Health Wales NHS Trust
- Scottish Medicines Consortium

#### Comparator manufacturers

- Accord healthcare (5-fluorouracil)
- Hospira UK (5-fluorouracil)
- Medac UK (5-fluorouracil)
- Wockhardt UK (5-fluorouracil)

#### Relevant research groups

- Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
- CORE- Digestive Disorders Foundation
- Institute of Cancer Research
- Health Research Authority
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Research Institute for the Care of Older People

#### Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

#### Associated Guideline Groups

- National Collaborating Centre for Cancer

<ul style="list-style-type: none"> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Nene CCG</li> <li>• NHS West Suffolk CCG</li> <li>• Welsh Government</li> </ul>	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>
---	--

**GE paper sign-off:** Janet Robertson, Associate Director – Technology Appraisals Programme

**Contributors to this paper:**

Technical Lead: Nwamaka Umeweni

Project Manager: Andrew Kenyon

17 June 2013